Eli Lilly & Co. is issuing $5 billion in bonds to support its acquisition of Morphic Holding Inc. The acquisition aims to expand therapies for chronic illnesses. The bond sale comes amidst market turbulence, with many companies looking to issue debt ahead of key economic data releases.